Scribe Therapeutics (SCTX)
Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to ad...
- Open
- 38.000
- High
- 38.600
- Low
- 30.751
- Prev. Close
- 37.250
- Volume
- 316.02K
- Turnover
- 10.85M
- Avg Price
- 34.320
- Bid/Ask Ratio
- 27.01%
- Amplitude
- 21.07%
- 52wk High
- 39.600
- Volume Ratio
- 0.41
- Turnover Ratio
- 4.63%
Scribe Therapeutics Analyst Rating
View moreForecast & Rating
Aug 25, 2026Price forecast
$56.0079.46%
Forecast & RatingStrong buy
3analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Global Report · 10 hours ago
The Misfit Economy: What Drive-Thru Coffee and Subsea Robots Tell Us About 2026
- Global Report · 12 hours ago
Tech Billionaires and Institutional Whales Reshape Cap Tables Across Unclassified Equities
- Weekly Review · Aug 22 at 12:40 AM
Weekly Recap | Scribe Therapeutics +64.64%, most brokers rate it buy
- rttnews · Aug 21 at 05:43 AM
Biotech Stocks At 52-Week Highs - SCTX Continues Rise After Nasdaq Debut, RPRX, HAE, TXG, LH
- benzinga_article · Aug 20 at 10:06 AM
Deere, Coinbase Global, Nordson And Other Big Stocks Moving Higher On Wednesday
- Market Beat · Aug 19 at 10:20 AM
Scribe Therapeutics (NASDAQ:SCTX) Sets New 52-Week High After Analyst Upgrade
